Slide 1: Travere Therapeutics Corporate Overview
Travere Therapeutics Corporate Overview August 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including but not limited to statements about: continued progress with FILSPARI in IgAN and in the commercial launch of FILSPARI in FSGS; statements regarding our products and products in development as potential best-
Slide 3: We are in rare for life.
We are in rare for life. At Travere Therapeutics, we are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent — that is why our
Slide 4: Four Strategic Growth Pillars Support Durable Long-Term Value Creation
Four Strategic Growth Pillars Support Durable Long-Term Value Creation CORE GROWTH DRIVER CORE GROWTH DRIVER POTENTIAL NEXT APPROVED MEDICINE NEW GROWTH PLATFORM Pegtibatinase as Civorebrutinib Continued growth of Successful launch of potential first disease complements the rare FILSPARI in IgAN FIL
Slide 5: Pipeline of Potential Best-in-Class Programs Targeting Rare Kidney and Metabolic Diseases
Pipeline of Potential Best-in-Class Programs Targeting Rare Kidney and Metabolic Diseases PROGRAM THERAPEUTIC AREA PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED COMMERCIAL FILSPARI® IgAN (sparsentan)1 FILSPARI® FSGS (sparsentan)2 Thiola EC® and Cystinuria Thiola® (tiopronin) Pegtibatinase HCU (TVT-05
Slide 6: FILSPARI: Clear Path to Durable Growth Through Leadership in Rare Kidney Disease
FILSPARI: Clear Path to Durable Growth Through Leadership in Rare Kidney Disease Multiple growth drivers support >$3B FILSPARI expansion Estimated potential peak sales opportunity in the U.S. Large and Expanding Differentiated Designed for Scalable Commercial Market Opportunity Clinical Profile Long
Slide 7: FILSPARI Commercial Momentum Accelerates as FSGS Expands the Growth Opportunity
FILSPARI Commercial Momentum Accelerates as FSGS Expands the Growth Opportunity $141M 2,012 U.S. net FILSPARI sales in 2Q26 New PSFs in 2Q26 96% Strong FSGS launch; growth vs 2Q25 Continued growth in IgAN Increasing breadth and Evolving IgAN landscape depth of prescriber base expanding the market Hi
Slide 8: Strong Commercial Momentum Supported by Significant Long-Term Growth Drivers
Strong Commercial Momentum Supported by Significant Long-Term Growth Drivers FILSPARI label expansion with FSGS approval <10% penetration of the 2,012 combined IgAN and FSGS addressable market provides significant runway for continued growth Strong execution across IgAN FILSPARI streamlined REMS and
Slide 9: FILSPARI in IgAN
01 FILSPARI in IgAN Most commonly prescribed medicine approved for IgAN in evolving treatment landscape FILSPARI in FSGS 02 Successfully launch first approved medicine in FSGS Pegtibatinase 03 First disease-modifying therapy for classical HCU, if approved Civorebrutinib 04 Pipeline-in-a-product pote
Slide 10: A Substantial Opportunity to Improve the Lives of Patients Living with IgAN
A Substantial Opportunity to Improve the Lives of Patients Living with IgAN 2025 KDIGO guidelines4 to drive earlier treatment peak incidence 25-39 age of IgAN1 and combination therapy market median time to kidney >70,000 addressable failure in high-risk patients5 ~11 yrs adult patients2 of transplan
Slide 11: Current KDIGO Guidelines: The IgAN Treatment Paradigm is Evolving
Current KDIGO Guidelines: The IgAN Treatment Paradigm is Evolving Earlier Treatment, Lower Proteinuria Targets and Simultaneous Therapy 1 2 3 Earlier At risk of progressive loss of kidney Treatment diagnosis function requiring treatment goal • Kidney biopsy in all adults • At risk if proteinuria ≥0.
Slide 12: The Shifting IgAN Treatment Paradigm: Two Areas to Target
The Shifting IgAN Treatment Paradigm: Two Areas to Target; Two Treatment Categories OVERACTIVATION IN THE KIDNEY OVERACTIVATION OF THE IMMUNE SYSTEM Foundational Treatment Immunosuppressant Treatment TARGET THE KIDNEY INJURY TARGET THE IMMUNE SYSTEM RASi Steroids Budesonide ± SGLT2i Complement Inhib
Slide 13: FILSPARI Positioned as a First-in-Class Foundational Treatment in IgAN
FILSPARI Positioned as a First-in-Class Foundational Treatment in IgAN with Best-in-Class Features Two-year safety data comparable to maximum-labeled dose irbesartan One pill, once daily administration Superior two-year proteinuria reduction vs active comparator irbesartan stronger foundation for ki
Slide 14: Paving a Path to Global Access for FILSPARI in IgAN
Paving a Path to Global Access for FILSPARI in IgAN with Established Commercial Partners Submitted New Drug >70k addressable patients with Application for sparsentan in IgAN1 Japan United States License to Chugai covers Japan, South Korea, and Taiwan Standard approval in Europe and the UK; FILSPARI
Slide 15: FILSPARI in FSGS
FILSPARI in IgAN 01 Most commonly prescribed medicine approved for IgAN in evolving treatment landscape FILSPARI in FSGS 02 Successfully launch first approved medicine in FSGS Pegtibatinase 03 First disease-modifying therapy for classical HCU, if approved Civorebrutinib 04 Pipeline-in-a-product pote
Slide 16: FSGS Represents Significant Patient and Community Burden
FSGS Represents Significant Patient and Community Burden Symptoms Side effects from of FSGS medications (IST) 7-year Fatigue 5-10 years kidney survival rate median time to for FSGS is the lowest | kidney failure for among primary High blood Significant toxicity 30-60% of glomerular diseases1 pressur
Slide 17: Proteinuria is the Primary Predictor of Disease Severity and Kidney Failure in FSGS
Proteinuria is the Primary Predictor of Disease Severity and Kidney Failure in FSGS Role of Elevated and Persistent Proteinuria in FSGS PROTEINURIA Podocyte Podocyte Glomerular Glomerular Tubulointerstitial injury1,2 Loss3,4,5 hypertrophy sclerosis1,2 fibrosis1,2 hyperfiltration6,7 KIDNEY FAILURE Ab
Slide 18: All Types of FSGS Share a Similar Glomerular Lesion Initiated by Podocyte Injury
Regardless of the Underlying Etiology, All Types of FSGS Share a Similar Glomerular Lesion Initiated by Podocyte Injury PRIMARY GENETIC UNDETERMINED CAUSE SECONDARY FSGS lesions with diffuse foot Identified genetic variants of FSGS lesions without diffuse Secondary to other disease process effacemen
Slide 19: KDIGO Guidelines Recommend FSGS Management
KDIGO Guidelines Patient with FSGS lesion on kidney biopsy1 Recommend FSGS Management ABSENCE OF PRESENCE OF Based on Nephrotic nephrotic syndrome nephrotic syndrome Syndrome Status Nephrotic-range proteinuria >3.5 g/d Proteinuria >3.5 g/d BUT AND Serum albumin >3.0 g/dl Serum albumin <3.0 g/dl OR w
Slide 20: Addressable FSGS Population Across Disease Subtypes is Expected to Grow Over Time
Addressable FSGS Population Across Disease Subtypes is Expected to Grow Over Time >30,000 addressable patients with clear drivers of future growth Future growth drivers: Population growth >30K PATIENTS ADDRESSABLE AT LAUNCH Secondary and Undetermined Cause ~10K Earlier referral to nephrologist in li
Slide 21: Strong Anticipation and Clinical Familiarity with FILSPARI Expected to Drive Utilization in FSGS
Strong Anticipation and Clinical Familiarity with FILSPARI Expected to Drive Utilization in FSGS >80% of nephrologists indicate novel non-immunosuppressives are highly desirable in FSGS1 ~70% of nephrologists report being “extremely familiar” with FILSPARI for FSGS1 ~90% of patients are already on A
Slide 22: Leveraging FILSPARI's Established Commercial Platform to Accelerate FSGS Adoption
Leveraging FILSPARI's Established Commercial Platform to Accelerate FSGS Adoption Patient & Established Access & Comprehensive Product Available Physician Focus Commercial Reimbursement Support Program Day 1 Infrastructure Continuous patient Experienced field Established payer Travere TotalCare Stre
Slide 23: Strategic Evidence Generation Expected to Further Support FILSPARI's Long-Term Growth Opportunity
Strategic Evidence Generation Expected to Further Support FILSPARI's Long-Term Growth Opportunity Evidence Generation Data Generation Potential Impact FILSPARI as first-line therapy ~70% proteinuria reduction Supports foundational therapy IgAN in newly diagnosed patients & eGFR stabilization (week 2
Slide 24: Pegtibatinase
FILSPARI in IgAN 01 Most commonly prescribed medicine approved for IgAN in evolving treatment landscape FILSPARI in FSGS 02 Successfully launch first approved medicine in FSGS Pegtibatinase 03 First disease-modifying therapy for classical HCU, if approved Civorebrutinib 04 Pipeline-in-a-product pote
Slide 25: HCU Market Represents Significant Unmet Need with Potential for Growth
HCU Market Represents Significant Unmet Need with Potential for Growth with Better Diagnostics, Awareness and Effective Treatment Options Disease education/awareness, enhanced diagnostics and better treatment options are expected to lead to increased patient identification, earlier diagnosis, and be
Slide 26: Pegtibatinase is an Investigational, Modified, Recombinant CBS Human Enzyme Therapy
Pegtibatinase is an Investigational, Modified, Recombinant CBS Human Enzyme Therapy Pegtibatinase is designed to address the underlying genetic cause of HCU Pegtibatinase has been granted multiple Mechanism of action is regulatory designations Methionine designed to have broad for the treatment of e
Slide 27: Phase 1/2 COMPOSE Study Showed Rapid and Sustained tHcy Reduction
Treatment with Pegtibatinase in the Phase 1/2 COMPOSE Study Showed Rapid and Sustained tHcy Reduction Through 12 Weeks of Treatment Summary of relative reduction in geometric mean of total homocysteine from baseline from 67.1% mean relative reduction in total cohorts 1-6 in the Phase 1/2 COMPOSE Stu
Slide 28: Innovative Pegtibatinase Phase Program Designed to Enable a BLA Submission
Innovative Pegtibatinase Phase 3 Program Designed to Enable a BLA Submission Screening 2-week dose Double-blind treatment Safety FU period ≤4 weeks ≤6 weeks titration 24 weeks 4 weeks Primary endpoint • Change from baseline in plasma Randomization (1:1) Phase 3 Pre-treatment DSP (N≈70) Pegtibatinase
Slide 29: On Track to Position Pegtibatinase as the First Potential Disease-Modifying Therapy in HCU
On Track to Position Pegtibatinase as the First Potential Disease-Modifying Therapy in HCU Phase 3 HARMONY Study enrollment continues Leveraging patient Activating clinical identification efforts to build sites globally enrollment momentum Patients continue to be Topline data on track for followed i
Slide 30: Civorebrutinib
FILSPARI in IgAN 01 Most commonly prescribed medicine approved for IgAN in evolving treatment landscape FILSPARI in FSGS 02 Successfully launch first approved medicine in FSGS Pegtibatinase 03 First disease-modifying therapy for classical HCU, if approved Civorebrutinib 04 Pipeline-in-a-product pote
Slide 31: Civorebrutinib is a Potent Covalent Reversible BTK Inhibitor
Civorebrutinib is a Potent Covalent Reversible BTK Inhibitor with Potential Across Several Immune-Mediated Rare Kidney Indications Civorebrutinib is a potential best-in-class BTK inhibitor differentiated by oral administration, with rapid onset of action, high selectivity, strong potency, and a pote
Slide 32: Civorebrutinib Offers Higher Selectivity and Potency Compared to Covalent Irreversible BTK inhibitors
Civorebrutinib Offers Higher Selectivity and Potency Compared to Covalent Irreversible BTK inhibitors Potential best-in-class 1 Reversible covalency 2 Excellent selectivity 3 Potent target binding 4 safety profile IC50 Selectivity (IC50 fold) Kinase IC50/BTK IC50 (fold) nM Compound BTKi BTK LCK SRC
Slide 33: Significant Diagnosed Patient Population Across Potential Rare Kidney Diseases
Diagnosed Prevalence Cases Across Immune-Mediated Rare Kidney Diseases >20k Significant Diagnosed Immune- mediated Patient Population FSGS2 Across Potential Rare Kidney Disease Opportunities >130k >20k >90k diagnosed patients MCD3 pMN1 across multiple indications Mechanistic rationale supports furth
Slide 34: Primary Membranous Nephropathy Remains a High Unmet Need with Significant Patient Burden
Primary Membranous Nephropathy Remains a High Unmet Need with Significant Patient Burden Symptoms of pMN ~60-70% of patients present with nephrotic syndrome1,2 “Brain Fog” Ophthalmic problems ~60% Fatigue of patients presenting with sub nephrotic- range proteinuria will progress to full nephrotic sy
Slide 35: BTK Inhibitors Target Multiple Key Nodes in the Pathogenesis of Primary Membranous Nephropathy
BTK Inhibitors Target Multiple Key Nodes in the Pathogenesis of Primary Membranous Nephropathy BTK inhibitors suppress B-cell signaling, BTK inhibitors provide functional B-cell Oral BTK inhibitors may allow for more reducing B-cell activation and modulation without broad b-cell or rapid recovery of
Slide 36: Phase 1b/2a Study of Civorebrutinib in Patients with pMN
Phase 1b/2a Study of Civorebrutinib in Patients with pMN with Positive Anti-PLA2R Autoantibody Part A Part B Low Dose: civorebrutinib (EVER001) 100mg QD×4W→ Follow-up Extended Follow-up Period 100mg BID×32W（N=13） Data from at least 8 pts 36 weeks treatment 16 weeks Up to Week 104 dosed for 10 days i
Slide 37: Civorebrutinib Demonstrated Rapid and Sustained Reductions in Key Disease Biomarkers (anti-PLA2R)
Phase 1/2 Proof of Concept: Civorebrutinib Demonstrated Rapid and Sustained Reductions in Key Disease Biomarkers Percent Change in Anti-PLA2R from Baseline (FAS) 0% Geometric LS Mean of Percent Change from Part A Follow-up Period -20% ~90% ~90% -40% Baseline, % -62.2% -60% reduction in reduction in
Slide 38: Civorebrutinib Demonstrated Rapid and Sustained Reductions in Key Disease Biomarkers (Proteinuria)
Phase 1/2 Proof of Concept: Civorebrutinib Demonstrated Rapid and Sustained Reductions in Key Disease Biomarkers 40% Percent Change in 24h Proteinuria from Baseline (FAS) Geometric LS Mean of Percent Change from Part A Follow-up Period 20% ~80% 0% ~80% reduction in Baseline, % -20% reduction in prot
Slide 39: Favorable Safety and Tolerability Profile
Favorable Safety and Tolerability Profile No clinically meaningful AEs typically associated with BTK inhibitors, such as neutropenia, hemorrhage, cardiac arrythmia Cohort 1 (N=13) Cohort 2 (N=18) Category of AEs, n (%) 100mg QD→ Total (N=31) 200mg BID 100mg BID Treatment emergent AE (TEAE) 12 (92.3)
Slide 40: Civorebrutinib is a Viable Candidate to Address Key Gaps in pMN Treatment
With the Potential for Rapid, Controllable Immune Modulation, Civorebrutinib is a Viable Candidate to Address Key Gaps in pMN Treatment Rapid and sustained reductions in key disease biomarkers seen in Phase 1/2 study (anti-PLA2R and proteinuria) Oral administration Convenient patient-friendly option
Slide 41: BTK Inhibitor Mechanism Has Promising Potential in Several Rare Kidney Diseases
BTK Inhibitor Mechanism Has Promising Potential in Several Rare Kidney Diseases, including Immune-Mediated FSGS and MCD BTK plays a functional role in immune cell types involved in FSGS pathology BTKi's have a potential role in FSGS with immune cell involvement BTKi’s target overactivation in the im
Slide 42: A Strong Financial Foundation to Deliver New Treatment Standards in Rare Disease
A Strong Financial Foundation to Deliver New Treatment Standards in Rare Disease ~$161M ~94M ~$489M ~$95M in total U.S. net basic shares in cash and cash in convertible product sales outstanding as of equivalents2 as of notes due in 2Q26 June 30, 2026 June 30, 2026 March 2029 Represents $525M due ~7
Slide 43: Data Appendix
Data Appendix
Slide 44: Treatment with FILSPARI May Potentially Delay Dialysis or Transplant
Treatment with FILSPARI May Potentially Delay Dialysis or Transplant Potential long-term impact of preserved eGFR slope1,2 60 50 Based on extrapolation of eGFR slope data from PROTECT, eGFR (mL/min/1.73 m2) 40 FILSPARI may potentially +4.5 years vs irbesartan FILSPARI delay dialysis or 30 Irbesartan
Slide 45: Further Evidence Generation to Drive Broad Uptake
Further Evidence Generation to Drive Broad Uptake: Supporting First-Line FILSPARI Use in Newly Diagnosed Patients 0 SPARTAN Study: Preliminary clinical findings at 24-weeks in −20 baseline, geometric mean treatment-naïve patients on Change in UPCR from FILSPARI −40 (SE), % FILSPARI led to rapid and
Slide 46: SPARTAN Study: Urinary Biomarker Analysis Suggests Disease-Modifying Effects of FILSPARI in IgAN
SPARTAN Study: Urinary Biomarker Analysis Suggests Disease-Modifying Effects of FILSPARI in IgAN Treatment with FILSPARI resulted in rapid and sustained reductions in urinary biomarkers of inflammation and fibrosis that reveal anti-inflammatory and anti-fibrotic effects of FILSPARI1 0 BAFF sC5b9 bio
Slide 47: SPARTACUS Study: FILSPARI Added to SGLT2i Resulted in Further Proteinuria Reduction
SPARTACUS Study: FILSPARI Added to SGLT2i Resulted in Further Proteinuria Reduction and Was Generally Well Tolerated Transitioning patients from RASi to FILSPARI resulted in a TEAEs Patients mean reduction in UACR of ~56% at 24 weeks (N=48) Any TEAE, n (%) 30 (63) 10 SPAR related 10 (21) Geometric l
Slide 48: The DUPLEX Study of Sparsentan is the Largest Active-Controlled Interventional Phase 3 Trial in FSGS
The DUPLEX Study of Sparsentan is the Largest Active- Controlled Interventional Phase 3 Trial in FSGS to Date Evaluate the efficacy • Phase 3, double-blind, active-controlled global trial in patients with biopsy-proven Objective and safety Trial Design FSGS or genetic FSGS, N=371 patients (ages 8 to
Slide 49: In DUPLEX, FILSPARI Demonstrated Even Greater Reduction in Proteinuria in FSGS without Nephrotic Syndrome
In DUPLEX, Treatment with FILSPARI Demonstrated Even Greater Reduction in Proteinuria in FSGS without Nephrotic Syndrome DUPLEX Population without Nephrotic Syndrome* Overall DUPLEX Population % reduction in UPCR from baseline by visit % reduction in UPCR from baseline by visit 0% 0% LS Mean Change
Slide 50: In DUPLEX, FILSPARI Demonstrated Even Greater Relative Proteinuria Reduction Across Thresholds
In DUPLEX, FILSPARI Demonstrated Even Greater Relative Proteinuria Reduction Across Thresholds in FSGS without Nephrotic Syndrome DUPLEX Population without Nephrotic Syndrome* Overall DUPLEX Population Patients achieving UPCR thresholds1, % Patients achieving UPCR thresholds1,2, % FILSPARI (N=129) I
Slide 51: In DUPLEX, FILSPARI Demonstrated a Clinically Meaningful Effect on eGFR
In DUPLEX, FILSPARI Demonstrated a Clinically Meaningful Effect on eGFR in FSGS without Nephrotic Syndrome DUPLEX Population without Nephrotic Syndrome* FILSPARI Irbesartan Difference p-value5 (N=129)1 (N=125)1 Adjusted Mean Change in eGFR (mL/min/1.73 m2) at Week 108 -11.3 -12.4 1.1 NS from baselin
Slide 52: In DUPLEX, FILSPARI Demonstrated Even Stronger Benefit on Exploratory Kidney Outcome Endpoints
In DUPLEX, FILSPARI Demonstrated Even Stronger Benefit on Exploratory Kidney Outcome Endpoints in FSGS without Nephrotic Syndrome FILSPARI showed clinically meaningful benefit in the broad DUPLEX population, with enhanced efficacy in population without nephrotic syndrome* 14 FILSPARI Irbesartan RR:
Slide 53: Inc .
© 2026 Inc. 2025 Travere Therapeutics, Inc.